What makes CLDN7 lose its #TumorSuppressive power?
This study shows that APT1-driven #depalmitoylation destabilizes CLDN7, promoting #ccRCC invasion and revealing APT1 inhibition as a potential therapy. @pku1898.bsky.social
#OpenAccess #GenesAndDiseases: doi.org/10.1016/j.ge...

FDA approval of post-surgery #pembro + belzutifan adds a treatment option for patients with higher-risk #ccRCC. But does it change practice? Read more from Dr. Stepan M. Esagian, Dr. Pavlos Msaouel, and Dr. Andrew W. Hahn for #ASCODailyNews: https://bit.ly/4ABHaF2